×
Components:
Aceclofenac
Method of action:
Nonsteroidal Anti-Inflammatory, Topical Products For Joint And Muscular Pain
Available in countries
See all
close
Medically reviewed by Fedorchenko Olga Valeryevna, Pharmacy-Provisor. Last updated on 2019.09.22

Name of the medicinal product

Aceclofenac Mylan

Qualitative and quantitative composition

Aceclofenac

Pharmaceutical form

Film-coated tablet

Therapeutic indications

The information provided in Therapeutic indications of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Aceclofenac Mylan film-coated tablets are indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Aceclofenac Mylan film-coated tablets are supplied for oral administration and should be swallowed whole with a sufficient quantity of liquid.

To be taken preferably with or after food. When Aceclofenac Mylan was administered to fasting and fed healthy volunteers only the rate and not the extent of Aceclofenac Mylan absorption was affected.

Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.

Adults

The recommended dose is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening.

Paediatric population

There are no clinical data on the use of Aceclofenac Mylan in children and therefore it is not recommended for use in children under 18 years of age.

Elderly

The elderly, who are more likely to be suffering from impaired renal, cardiovascular or hepatic function and receiving concomitant medication, are at increased risk of serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.

The pharmacokinetics of Aceclofenac Mylan are not altered in elderly patients, therefore it is not considered necessary to modify the dose or dose frequency.

Renal insufficiency

There is no evidence that the dosage of Aceclofenac Mylan needs to be modified in patients with mild renal impairment, but as with other NSAIDs caution should be exercised.

Hepatic insufficiency

There is some evidence that the dose of Aceclofenac Mylan should be reduced in patients with hepatic impairment and it is suggested that an initial daily dose of 100 mg be used.

Method of administration

Swallow the tablet whole with a glass of water. Do not crush or chew the tablets. Never change the dose of your medicine without talking to your doctor first. Continue to take your tablets for as long as your doctor recommends.

Contraindications

The information provided in Contraindications of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Hypersensitivity to Aceclofenac Mylan or to any of the excipients.

Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).

History of active bleedings or bleeding disorders

NSAIDS are contraindicated in patients who have previously shown hypersensitivity reactions (e.g. Asthma, rhinitis, angioedema or urticaria) in response to ibuprofen, aspirin, or other non-steroidal anti-inflammatory drugs.

Patients with established congestive heart failure (NYHA class II-IV), ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

Severe heart failure, hepatic failure and renal failure.

History of gastrointestinal bleeding or perforation, related to previous NSAIDS therapy.

Aceclofenac Mylan should not be prescribed during pregnancy, especially during the last trimester of pregnancy, unless there are compelling reasons for doing so. The lowest effective dosage should be used.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

The use of Aceclofenac Mylan with concomitant NSAIDs including cyclooxygenase- 2 selective inhibitors should be avoided.

Elderly:

The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.

Respiratory disorders:

Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.

Cardiovascular, Renal and Hepatic Impairment:

The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure.).

Renal:

The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. The importance of prostaglandins in maintaining renal blood flow should be taken into account in patients with impaired cardiac or renal function, liver dysfunction, those being treated with diuretics or recovering from major surgery. Effects on renal function are usually reversible on withdrawal of Aceclofenac Mylan Tablets.

Patients with mild to moderate renal impairment should be kept under surveillance, since the use of NSAIDs may result in deterioration of renal function. The lowest effective dose should be used and renal function monitored regularly. Effects on renal function are usually reversible on withdrawal of Aceclofenac Mylan.

Hepatic:

If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur (eosinophilia, rash), Aceclofenac Mylan Tablets should be discontinued. Close medical surveillance is necessary in patients suffering from mild to moderate impairment of hepatic function. Hepatitis may occur without prodromal symptoms.

Use of NSAIDs in patients with hepatic porphyria may trigger an attack.

Cardiovascular and cerebrovascular effects:

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. As the cardiovascular risks of Aceclofenac Mylan may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re- evaluated periodically.

Aceclofenac Mylan should also be administered with caution and under close medical surveillance to patients with congestive heart failure, significant risk factors for cardiovascular events and history of cerebrovascular bleeding.

Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for Aceclofenac Mylan.

Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Aceclofenac Mylan after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).

Gastrointestinal bleeding, ulceration and perforation:

GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.

Close medical surveillance is imperative in patients with:

- symptoms indicative of gastro-intestinal disorders involving either the upper or lower gastrointestinal tract

- with a history suggestive of gastro-intestinal ulceration, bleeding or perforation

- with ulcerative colitis or with Crohn's disease

- bleeding diathesis or haematological abnormalities.

The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation , and in the elderly.).

Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or antiplatelet agents such as aspirin.

When GI bleeding or ulceration occurs in patients receiving Aceclofenac Mylan, the treatment should be withdrawn.

NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated.

SLE and mixed connective tissue disease:

In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.

Dermatological:

Impaired female fertility:

The use of Aceclofenac Mylan Tablets may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Aceclofenac Mylan Tablets should be considered.

Hypersensitivity/Dermatological reactions:

As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Jonson syndrome, and toxic epidermal necrolysis, have been reporting very rarely in association with the use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Aceclofenac Mylan should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Exceptionally, varicella can trigger serious cutaneous and soft tissues infections complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of Aceclofenac Mylan in case of varicella.

Haematological:

Aceclofenac Mylan Tablets may reversibly inhibit platelet aggregation (see anticoagulants under 'Interactions').

Long-term treatment:

All patients who are receiving NSAIDs should be monitored as a precautionary measure e.g. renal failure, hepatic function (elevation of liver enzymes may occur) and blood counts.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Undesirable effects such as dizziness, vertigo, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected, patients should not drive or operate machinery.

Undesirable effects

The information provided in Undesirable effects of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Exceptionally, occurrence of serious cutaneous and soft tissues infections complications during varicella has been reported in association with NSAID treatment.

Aceclofenac Mylan is both structurally related and metabolised to diclofenac for which a greater amount of clinical and epidemiological data consistently point towards an increased risk of general arterial thrombotic events (myocardial infarction or stroke, particularly at high doses and in long treatment).4 for contraindication and Special warnings and special precautions for use).

Gastrointestinal:

The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported following administration. Less frequently, gastritis has been observed. Pancreatitis has been reported very rarely.

Hypersensitivity:

Hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angiodema and, more rarely exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme).

Cardiovascular:

Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.

Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke).

Other adverse reactions reported less commonly include:

Renal:

Nephrotoxicity in various forms, including interstitial nephritis, nephritic syndrome and renal failure.

Hepatic:

abnormal liver function, hepatitis and jaundice.

Neurological and special senses:

Visual disturbances, optic neuritis, headaches, paraesthesia, reports of aseptic meningitis (especially in patients with existing auto-immune disorders, such as systemic lupus erythematosus, mixed connective tissue disease), with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation , depression, confusion, hallucinations, tinnitus, vertigo, dizziness, malaise, fatigue and drowsiness.

Haematological:

Thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia.

Dermatological:

Bullous reactions including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (very rare). Photosensitivity.

Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System organ class

Common

(>1/100 to <1/10)

Uncommon

(>1/1,000 to <1/100)

Rare

(>1/10,000 to <1/1,000)

Very rare/ isolated reports (<1/10,000)

Blood and lymphatic system disorders

Anaemia

Bone Marrow depression, Granulocytopenia

Thrombocytopenia

Neutropenia

Haemolytic anaemia

Immune system disorders

Anaphylactic reaction (including shock)

Hypersensitivity

Metabolism and nutrition disorders

Hyperkalemia

Psychiatric disorders

Depression

Abnormal dreams

Insomnia

Nervous system disorders

Dizziness

Paraesthesia

Tremor

Somnolence

Headache

Dysgeusia (abnormal taste)

Eye disorders

Visual disturbance

Ear and labyrinth disorders

Vertigo

Tinnitus

Cardiac disorders

Cardiac failure

Palpitations

Vascular disorders

Hypertension

Flushing

Hot flush

vasculitis

Respiratory, thoracic and mediastinal disorders

Dyspnoea

Bronchospasm

Stridor

Gastrointestinal disorders

Dyspepsia

Abdominal pain

Nausea

Diarrhoea

Flatulence

Gastritis

Constipation

Vomiting

Mouth ulceration

Melaena

Gastrointestinal haemorrhage

Gastrointestinal ulceration

Stomatitis

Intestinal perforation

Exacerbation of Crohn's disease and colitis Ulcerative

Haematemesis

Gastrointestinal haemorrhage

Gastric ulcer

Pancreatitis

Skin and subcutaneous tissue disorders

Pruritus

Rash

Dermatitis

Urticaria

Face oedema

Angioedema

Purpura

Severe mucocutaneous skin reaction (including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis)

Dermatitis bullous

Musculoskeletal and connective tissue disorders

Cramps in the leg

Renal and urinary disorders

Blood urea increased

Blood creatinine increased

Renal insufficiency

Nephrotic syndrome

Renal failure

Hepatobiliar disorders

Hepatic enzyme increased

Hepatitis

Jaundice

Hepatic injury (including hepatitis)

Blood alkaline phosphatase increased

General disorders and administration site conditions

Oedema

Fatigue

Cramps in legs

Investigations

Weight increase

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Overdose

The information provided in Overdose of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

There is insufficient data available on the consequences of Aceclofenac Mylan in humans.

a) Symptoms

Symptoms include headache, nausea, vomiting, epigastric pain, gastrointestinal irritation, gastrointestinal bleeding, rarely diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, hypotension, respiratory depression, fainting, occasionally convulsions. In cases of significant poisoning acute renal failure and liver damage are possible.

b) Therapeutic measure:

Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially toxic amount, activated charcoal should be considered. Alternatively, in adults, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose.

Given the route of administration and the pharmaceutical form, an overdose with injectable Aceclofenac Mylan is unlikely.

Specific therapies such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs due to their high rate of protein binding and extensive metabolism. Good urine output should be ensured.

Renal and liver function should be closely monitored. Patients should be observed for at least four hours after ingestion of potentially toxic amounts. In case of frequent or prolonged convulsions, patients should be treated with intravenous diazepam. Other measures may be indicated by the patient's clinical condition.

Management of acute poisoning with NSAIDs essentially consists of supportive and symptomatic measures.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Aceclofenac Mylan is a non-steroidal agent with marked anti-inflammatory and analgesic properties.

ATC code: M01A B16

The mode of action of Aceclofenac Mylan is largely based on the inhibition to prostaglandin synthesis. Aceclofenac Mylan is a potent inhibitor of the enzyme cyclo-oxygenase, which is involved in the production of prostaglandins.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

After oral administration, Aceclofenac Mylan is rapidly and completely absorbed as unchanged drug. Peak plasma concentrations are reached approximately 1.25 to 3.00 hours following ingestion. Aceclofenac Mylan penetrates into the synovial fluid, where the concentrations reach approximately 57% of those in plasma. The volume of distribution is approximately 25 L.

The mean plasma elimination half-life is around 4 hours. Aceclofenac Mylan is highly protein- bound (>99%). Aceclofenac Mylan circulates mainly as unchanged drug. 4'- hydroxyAceclofenac Mylan is the main metabolite detected in plasma. Approximately two- thirds of the administered dose is excreted via the urine, mainly as hydroxymetabolites.

No changes in the pharmacokinetics of Aceclofenac Mylan have been detected in the elderly.

Preclinical safety data

The information provided in Preclinical safety data of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

The results from preclinical studies conducted with Aceclofenac Mylan are consistent with those expected for NSAIDs. The principal target organ was the gastro-intestinal tract.

No unexpected findings were recorded.

Aceclofenac Mylan was not considered to have any mutagenic activity in three in vitro studies and an in vivo study in the mouse.

Aceclofenac Mylan was not found to be carcinogenic in either the mouse or rat.

Incompatibilities

The information provided in Incompatibilities of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of Aceclofenac Mylan is based on data of another medicine with exactly the same composition as the Aceclofenac Mylan of the medicine (Aceclofenac). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Aceclofenac Mylan directly from the package or from the pharmacist at the pharmacy.
more... close

Any unused product or waste material should be disposed of in accordance with local requirements.